Needham & Company Maintains a 'Buy' on Micromet (MITI); Data Strongly Support Pivotal Testing in 2012

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

June 13, 2011 8:09 AM EDT
Get Alerts MITI Hot Sheet
Price: $0.03 --0%

Rating Summary:
    1 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on Micromet (NASDAQ: MITI), PT $13.

Needham analyst says, "We are positively inclined towards the blinatumomab development plan. We note little competition in this space after a review of the ASCO and EHA Meeting presentations in adult r/r ALL. We note multiple data presentations as potential stock catalysts, including updated data from a Phase 1 trial in r/r NHL (ICML, Lugano, June 16), initiation of a Phase 1/2 trial of blinatumomab in pediatric ALL (mid-2011), and final data from the Phase 2 trial described above (ASH Meeting, December 10-13, 2011)."

For more ratings news on Micromet click here and for the rating history of Micromet click here.

Shares of Micromet closed at $5.75 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Needham & Company